In an editorial, researchers discussed active and effective measures for the care of patients with cancer during the coronavirus disease 2019 (COVID-19) in China.
Despite positive trends, researchers found that substantial differences in the representation of gender in oncology publications by author role, article type, citation count, and credentials persist.
Incyte announced that they are working with the FDA to initiate a phase III clinical trial to assess ruxolitinib (Jakafi) plus standard-of-care in patients with coronavirus disease 2019 (COVID-19) induced cytokine storm.
The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival.
A 1-year follow-up of the phase II ZUMA-2 study found that KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma.
The director of the National Institute of Allergy and Infectious Diseases spoke with The New England Journal of Medicine in a podcast about how physicians can approach talking to patients regarding COVID-19.
Two separate studies of pediatric patients in Wuhan, China found that though clinical manifestations of COVID-19 in children were less severe than those of adult patients, young children, particularly infants, were vulnerable to the infection.
The FDA granted fast track designation to ME-401, an investigational selective oral inhibitor of PI3K delta, for the treatment of adult patients with relapsed or refractory follicular lymphoma.
In a letter to Congress, the AACR called for immediate action to be taken to protect patients with cancer against the COVID-19 pandemic.